多家明星药企,带来亮眼成绩单。8月26日,映恩生物公告,上半年总营收12.29亿元,调整后利润1.46亿元,现金总额达到37.47亿元。康诺亚也是在同一天宣布,上半年营收4.99亿元,同比暴增812%,其中包括合作收入3.29亿元。研发支出3.60亿元,同比增长9%。礼来口服GLP-1一项3期临床成功。8月26日,礼来公布了其在研GLP-1受体激动剂orforglipron的3期临床试验...
Source Link多家明星药企,带来亮眼成绩单。8月26日,映恩生物公告,上半年总营收12.29亿元,调整后利润1.46亿元,现金总额达到37.47亿元。康诺亚也是在同一天宣布,上半年营收4.99亿元,同比暴增812%,其中包括合作收入3.29亿元。研发支出3.60亿元,同比增长9%。礼来口服GLP-1一项3期临床成功。8月26日,礼来公布了其在研GLP-1受体激动剂orforglipron的3期临床试验...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.